Verastem Inc (VSTM)

Jan 15, 2025, 7:30 AM EST - 2 days ago

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

Jan 14, 2025, 7:30 AM EST - 3 days ago

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

Jan 13, 2025, 7:30 AM EST - 4 days ago

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

Jan 8, 2025, 7:30 AM EST - 9 days ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 3, 2025, 11:56 AM EST - 14 days ago

Verastem: Planning The PDUFA Run-Up

Jan 2, 2025, 11:39 AM EST - 15 days ago

Verastem: BLA Acceptance Puts Key Goals In Sight

Dec 31, 2024, 10:59 AM EST - 17 days ago

Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday?

Dec 30, 2024, 4:30 PM EST - 18 days ago

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Dec 18, 2024, 7:30 AM EST - 4 weeks ago

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Nov 27, 2024, 1:28 PM EST - 7 weeks ago

Verastem: Preparing For Upcoming Catalysts

Nov 26, 2024, 7:00 AM EST - 7 weeks ago

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

Nov 6, 2024, 4:05 PM EST - 2 months ago

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Oct 31, 2024, 4:01 PM EDT - 2 months ago

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Oct 31, 2024, 7:30 AM EDT - 2 months ago

Verastem Oncology to Participate in Upcoming Investor Conferences

Oct 17, 2024, 1:00 AM EDT - 3 months ago

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting

Oct 9, 2024, 6:00 AM EDT - 3 months ago

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

Sep 10, 2024, 4:05 PM EDT - 4 months ago

Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference

Sep 10, 2024, 7:30 AM EDT - 4 months ago

Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting

Sep 5, 2024, 11:21 PM EDT - 4 months ago

Verastem's Path To FDA Approval: High-Risk, High-Reward Oncology Opportunity

Sep 3, 2024, 7:30 AM EDT - 4 months ago

Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024

Aug 8, 2024, 4:05 PM EDT - 5 months ago

Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates

Jul 29, 2024, 4:01 PM EDT - 6 months ago

Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer

Jul 23, 2024, 11:20 PM EDT - 6 months ago

Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants

Jul 23, 2024, 4:05 PM EDT - 6 months ago

Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants

Jul 12, 2024, 7:30 AM EDT - 6 months ago

Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics

Jul 10, 2024, 2:48 PM EDT - 6 months ago

Verastem, Inc. Investors: Company Investigated by the Portnoy Law Firm

Jul 1, 2024, 7:30 AM EDT - 7 months ago

Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes

Jun 10, 2024, 10:51 AM EDT - 7 months ago

Verastem: Market Overreaction Creates A Dip Buying Opportunity

May 26, 2024, 2:02 AM EDT - 8 months ago

Verastem: A Shocking Drop On 'Positive' Data (Maintain Buy)

May 24, 2024, 11:30 AM EDT - 8 months ago

Verastem opened 70% down on Friday: what happened?

May 24, 2024, 7:30 AM EDT - 8 months ago

Harvest ETFs announces May 2024 Distributions

CLF

May 24, 2024, 7:00 AM EDT - 8 months ago

Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

May 23, 2024, 6:58 PM EDT - 8 months ago

Verastem shares surge more than 50% after pancreatic-cancer treatment study data

May 23, 2024, 5:01 PM EDT - 8 months ago

Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer​

May 9, 2024, 4:02 PM EDT - 9 months ago

Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates

May 7, 2024, 7:30 AM EDT - 9 months ago

Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference

Apr 18, 2024, 4:05 PM EDT - 9 months ago

Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer

Mar 18, 2024, 7:00 AM EDT - 10 months ago

Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer

Mar 14, 2024, 4:05 PM EDT - 11 months ago

Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

Mar 11, 2024, 7:30 AM EDT - 11 months ago

Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women's Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs

Mar 5, 2024, 5:27 PM EST - 11 months ago

Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Mar 5, 2024, 4:30 PM EST - 11 months ago

Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024

Feb 7, 2024, 1:01 AM EST - 1 year ago

Verastem: Other Catalysts In 2024 Beyond NDA Rolling Submission Of Defactinib

Jan 29, 2024, 7:00 AM EST - 1 year ago

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers